Immunosuppression Does Not Reduce Antitumor Efficacy

I read with great interest the paper by Mahmood et al. The authors conducted a very valuable and interesting study of 35 patients with immune checkpoint inhibitor (ICI)-associated myocarditis compared with 105 ICI-treated patients without myocarditis in a multicenter registry with 8 sites. The study found that myocarditis developed at a median of 34 days in patients receiving ICIs for the treatment of cancer. Moreover, the authors indicated that there were higher serum troponin levels and major adverse cardiac event rates with the use of lower steroid doses; higher steroid doses were associated with lower serum troponin levels and major adverse cardiac event rates in ICI-treated patients with myocarditis.